In my view, the company is likely to be bought out or partner with a medical major in the next 6 to 12 months as it could well be the end game of WP and the institution investors. NASDAQ IPO will just make it easier to happen.
Also, the impending head-to-head non-inferior trial against the incumbents won’t be a good thing for Edwards and alike if the performance of their valves display consistent inferior results against DurAVR.
Not advice DYOR
AVR Price at posting:
$7.42 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)